Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Human BRAF Antikörper:
anti-Rat (Rattus) BRAF Antikörper:
anti-Mouse (Murine) BRAF Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Human Polyclonal BRAF Primary Antibody für FACS, WB - ABIN1881118
Hingorani, Jacobetz, Robertson, Herlyn, Tuveson: Suppression of BRAF(V599E) in human melanoma abrogates transformation. in Cancer research 2003
Show all 6 Pubmed References
Human Monoclonal BRAF Primary Antibody für IHC, ELISA - ABIN1724658
Rapp, Goldsborough, Mark, Bonner, Groffen, Reynolds, Stephenson: Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. in Proceedings of the National Academy of Sciences of the United States of America 1983
Show all 5 Pubmed References
Human Monoclonal BRAF Primary Antibody für IHC, ELISA - ABIN965693
Kim, Giuliano, Turner, Gaffney, Umetani, Kitago, Elashoff, Hoon: Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. in Annals of surgery 2006
Show all 5 Pubmed References
Human Monoclonal BRAF Primary Antibody für ICC, IHC - ABIN968991
Di Nicolantonio, Martini, Molinari, Sartore-Bianchi, Arena, Saletti, De Dosso, Mazzucchelli, Frattini, Siena, Bardelli: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008
Show all 2 Pubmed References
Human Monoclonal BRAF Primary Antibody für PLA, ELISA - ABIN513800
Liu, Chen, Chau, Jan, Chen, Hsu, Lin, Juang, Lu, Cheng, Chen, Chang, Ting, Kao, Hsiao, Huang: Analysis of protein-protein interactions in cross-talk pathways reveals CRKL protein as a novel prognostic marker in hepatocellular carcinoma. in Molecular & cellular proteomics : MCP 2013
Human Polyclonal BRAF Primary Antibody für ELISA, IHC (p) - ABIN5573331
Wiggans, Reilly, Kass, Maggs: Histologic and immunohistochemical predictors of clinical behavior for feline diffuse iris melanoma. in Veterinary ophthalmology 2016
Human Polyclonal BRAF Primary Antibody für DB - ABIN389897
Frattini, Ferrario, Bressan, Balestra, De Cecco, Mondellini, Bongarzone, Collini, Gariboldi, Pilotti, Pierotti, Greco: Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. in Oncogene 2004
Show all 3 Pubmed References
BRAF mutations more frequently affected individuals younger than 61 with phototype II. In contrast, NRAS (zeige NRAS Antikörper) mutations were more frequent in phototype III cases. Mutations of both genes were more frequent in cases with satellitosis in the first melanoma, and in cases with ulceration in the subsequent lesions.
Identification of KRAS/NRAS/BRAF mutation status is crucial to predict the therapeutic effect and determine individual therapeutic strategies for patients with colorectal cancer.
we did not observe GNAS (zeige GNAS Antikörper) or BRAF mutations in urachal adenocarcinomas
Study finds infrequent BRAF alterations but enriched FGFR (zeige FGFR2 Antikörper) alterations in adults as compared with that reported in pediatric pilocytic astrocytomas. In addition, coexistent BRAF and FGFR (zeige FGFR2 Antikörper) alterations and a significant association of FGFR (zeige FGFR2 Antikörper) alterations with age and tumor location were noted.
a low frequency of BRAF or KRAS mutation in Chinese patients with low-grade serous carcinoma of the ovary
genetic association studies in population in China: Data suggest that, in patients with unilateral papillary thyroid carcinoma, a mutation in BRAF (V600E) plus multi-focality are both independently and synergically associated with CLNM (central lymph node metastasis) in the population studied.
RHEB (zeige RHEB Antikörper) Y35N expressing cells undergo cancer transformation due to decreased interaction between RHEB (zeige RHEB Antikörper) and BRAF resulting in overactive RAF (zeige RAF1 Antikörper)/MEK (zeige MAP2K1 Antikörper)/ERK (zeige EPHB2 Antikörper) signaling. Taken together with the previously established function of RHEB (zeige RHEB Antikörper) to activate mTORC1 signaling, it appears that RHEB (zeige RHEB Antikörper) performs a dual function; one is to suppress the RAF (zeige RAF1 Antikörper)/MEK (zeige MAP2K1 Antikörper)/ERK (zeige EPHB2 Antikörper) signaling and the other is to activate mTORC1 signaling.
The MLH1 (zeige MLH1 Antikörper)-93 AA genotype is significantly associated with promoter hypermethylation and MLH1 (zeige MLH1 Antikörper) loss in the context of Sessile serrated adenoma of dysplasia. BRAF mutant microsatellite stable colorectal cancers with the AA genotype most likely arise in traditional serrated adenomas since the A allele does not predispose to methylation in this context.
Knowing the mutation status of KRAS, BRAF or PIK3CA (zeige PIK3CA Antikörper) in stage II colorectal cancer can significantly improve the accuracy of prognoses.
Mutated Liquid-based FNAs BRAF, N/HRAS (zeige HRAS Antikörper) and TERT (zeige TERT Antikörper) mutations were significantly associated with malignancy regardless of the cytological classification
BRAF alternative splicing is differentially regulated in vertebrates. Exon 9b is present in all vertebrates, including Xenopus, but exon 8b is present only in eutherians.
Gene expression studies nominated TWIST2 (zeige TWIST2 Antikörper) as a key effector downstream of BRAF.
BRAF alternative splicing is differentially regulated in vertebrates. Exon 9b is present in all vertebrates, including Danio rerio, but exon 8b is present only in eutherians.
BRAF activation is sufficient for f-nevus formation, and is among the primary events in melanoma development.
BRAF alternative splicing is differentially regulated in rodent and primates. Exon 9b is present in vertebrates but exon 8b is present only in eutherians.
mosaic expression of BRAF(V600E) in mouse erythro-myeloid progenitors results in clonal expansion of tissue-resident macrophages and a severe late-onset neurodegenerative disorder
CDX2 (zeige CDX2 Antikörper)(Null)/BRAF(V600E) expression in adult mouse intestinal epithelium led to serrated morphology tumors (including carcinomas) and BRAF(V600E) potently interacted with CDX2 (zeige CDX2 Antikörper) silencing to alter gene expression. Like human serrated lesions, CDX2 (zeige CDX2 Antikörper)(Null)/BRAF(V600E)-mutant epithelium expressed gastric markers.
expression of an endogenous Braf(D631A) kinase-inactive isoform in mice (corresponding to the human BRAF(D594A) mutation) triggers lung adenocarcinoma in vivo, indicating that BRAF-inactivating mutations are initiating events in lung oncogenesis
TTM (zeige SLITRK1 Antikörper) reduces copper levels and MAPK (zeige MAPK1 Antikörper) signaling, thereby inhibiting BRAF(V600E)-driven melanoma tumor growth.
BRAF and ROKalpha (zeige ROCK2 Antikörper) form independent RAF1 (zeige RAF1 Antikörper) complexes in embryonic fibroblasts (MEFs) treated with epidermal growth factor (EGF (zeige EGF Antikörper)).
Braf(V600E) expression, coupled with simultaneous p53 (zeige TP53 Antikörper) ablation, permits bypass of senescence and progression to lung adenocarcinoma.
These results provide support for the role of BRAF(V600E) in metastasis.
Mechanistically, BRAF and RAF1 (zeige RAF1 Antikörper) operate independently to balance MAPK (zeige MAPK1 Antikörper) signaling: BRAF promotes ERK (zeige EPHB2 Antikörper) activation, while RAF1 (zeige RAF1 Antikörper) dims stress kinase activation.
Mass spectrometry based screening for potential interaction partners revealed that BRAF interacts and phosphorylates PAX3 (zeige PAX3 Antikörper).
Using a conditional allele for Braf(V600E) , a mutation observed in clinical cases of GIST, authors observed that Braf(V600E) activation was sufficient to drive ICC hyperplasia but not GIST tumorigenesis.
This gene encodes a protein belonging to the raf/mil family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene are associated with cardiofaciocutaneous syndrome, a disease characterized by heart defects, mental retardation and a distinctive facial appearance. Mutations in this gene have also been associated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung. A pseudogene, which is located on chromosome X, has been identified for this gene.
94 kDa B-raf protein
, B-Raf proto-oncogene serine/threonine-protein kinase (p94)
, murine sarcoma viral (v-raf) oncogene homolog B1
, proto-oncogene B-Raf
, serine/threonine-protein kinase B-raf
, v-raf murine sarcoma viral oncogene homolog B1
, B-Raf proto-oncogene serine/threonine-protein kinase
, proto-oncogene c-Rmil
, rmil serine/threonine-protein kinase
, serine/threonine kinase
, serine/threonine-protein kinase Rmil
, serine/threonine protein kinase BRAF
, serine/threonine-protein kinase B-raf-like
, B-raf protein